Sun Of India Agrees With Sanofi Of France To Delay Marketing Generic
This article was originally published in PharmAsia News
Executive Summary
India's Sun Pharmaceutical Industries reached an agreement with Sanofi-Aventis to settle a U.S. case by ceasing to sell a generic of a cancer drug after June 30
|
India's Sun Pharmaceutical Industries reached an agreement with Sanofi-Aventis to settle a U.S. case by ceasing to sell a generic of a cancer drug after June 30. The court case involved a generic of France-based Sanofi's Eloxatin (oxaliplatin) drug for treating cancer. Sanofi sued Sun for making a generic of its drug, but settled it out of court by agreeing to keep the Sun version off the market until August, 2012. Sun's Caraco Pharmaceutical Laboratories unit launched its generic in March, but under the settlement it is to be withdrawn from the market for more than two years. (Click here for more) "India's Sun Pharma To Stop Selling Eloxatin Generic" - Reuters (U.K.) (6/28/10) |